Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice
- 1 May 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 73 (9), S19-S22
- https://doi.org/10.1097/00007890-200205151-00004
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1Transplantation, 2002
- Therapeutic drug monitoring of immunosuppressant drugs in clinical practiceClinical Therapeutics, 2002
- Neoral C2 in liver transplant recipientsTransplantation Proceedings, 2001
- Benefits of cyclosporine microemulsion (Neoral) C2 monitoring are sustained at 1 year in de novo liver transplant recipientsTransplantation Proceedings, 2001
- Optimization of cyclosporine exposure utilizing C2 level monitoring in de novo renal transplant recipients: the toronto general hospital experienceTransplantation Proceedings, 2001
- Single-center study utilizing C2 level as monitoring tool in de novo renal transplant recipients treated with neoralTransplantation Proceedings, 2001
- ABSORPTION PROFILING OF CYCLOSPORINE MICROEMULSION (NEORAL) DURING THE FIRST 2 WEEKS AFTER RENAL TRANSPLANTATION1Transplantation, 2001
- Approaching the Therapeutic Window for Cyclosporine in Kidney TransplantationJournal of the American Society of Nephrology, 2001
- C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* FormulationBioDrugs, 2001